Antiplatelet and Anticoagulation Therapy 2012
DOI: 10.1007/978-1-4471-4297-3_1
|View full text |Cite
|
Sign up to set email alerts
|

Antiplatelet Agents: Current and Novel

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 74 publications
0
4
0
Order By: Relevance
“…Regarding aspirin's mode of action, it is an inhibitor of the cyclooxygenase type 2 enzyme, present in endothelial cells and consequently inhibits the conversion of AA into PGG2 and PGH2, which results in an inhibition of PGI2. This inhibition has the consequence of PGI2 not binding to the IP receptor, present in SMC [110]. Regarding L-NAME, this is considered a non-selective inhibitor of eNOS widely used as a pharmacological tool [111].…”
Section: Endothelium-derived Hyperpolarization Factormentioning
confidence: 99%
“…Regarding aspirin's mode of action, it is an inhibitor of the cyclooxygenase type 2 enzyme, present in endothelial cells and consequently inhibits the conversion of AA into PGG2 and PGH2, which results in an inhibition of PGI2. This inhibition has the consequence of PGI2 not binding to the IP receptor, present in SMC [110]. Regarding L-NAME, this is considered a non-selective inhibitor of eNOS widely used as a pharmacological tool [111].…”
Section: Endothelium-derived Hyperpolarization Factormentioning
confidence: 99%
“…Interaction with collagen or thrombin also leads to synthesis of TXA2 from arachidonic acid (AA) liberated from phospholipids within the activated platelets, and also secretion of the contents of storage granules that include ADP. The TXA2 and the ADP contribute further to the platelet aggregation [2,5].…”
Section: Approaches To Assessment Of Platelet Reactivitymentioning
confidence: 99%
“…For example, aspirin inhibits aggregation brought about by AA as it blocks the cyclo-oxygenase involved in converting this into TXA2. Clopidogrel and newer P2Y12 antagonists, such as prasugrel, ticagrelor and cangrelor reduce the extent of the platelet aggregation brought about by ADP by interfering with the ability of ADP to interact with P2Y12 receptors on the platelet surface [5].…”
Section: Light Transmission Aggregometrymentioning
confidence: 99%
See 1 more Smart Citation